| Authors: |
Richardson PG; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: paul_richardson@dfci.harvard.edu., Perrot A; CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France., San-Miguel J; Clínica Universidad de Navarra, Navarra, CCUN, CIMA, IDISNA, CIBER-ONC, Pamplona, Spain., Beksac M; Department of Hematology, Ankara University, Ankara, Turkey., Spicka I; General Faculty Hospital, and First Faculty of Medicine, Charles University, Prague, Czech Republic., Leleu X; Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France., Schjesvold F; Oslo Myeloma Center, Department of Haematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Moreau P; Hematology Department, CHU Nantes, Nantes, France., Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens School of Medicine, Athens, Greece., Huang JS; Department of Hematology, National Taiwan University Hospital, Taipei, Taiwan., Minarik J; Department of Hemato-Oncology, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic., Cavo M; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy., Prince HM; Immunology and Molecular Oncology, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia., Malinge L; Sanofi R&D, Vitry, France., Dubin F; Sanofi R&D, Vitry, France., van de Velde H; Sanofi R&D, Vitry, France., Anderson KC; Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. |
